Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280156 | 0.88 | SMPD1 (0.36) | SMPD1 | |
| SCHEMBL17898553 | 0.86 | CA1 (0.31) | CA1 | |
| SCHEMBL8742968 | 0.83 | SMPD1 (0.33) | SMPD1 | |
| SCHEMBL3280344 | 0.81 | SMPD1 (0.38) | SMPD1 | |
| SCHEMBL12953253 | 0.79 | SMPD1 (0.39) | SMPD1 | |
| SCHEMBL8742389 | 0.77 | SMPD1 (0.35) | SMPD1 | |
| SCHEMBL3283840 | 0.74 | SMPD1 (0.38) | SMPD1 | |
| SCHEMBL3280534 | 0.74 | SMPD1 (0.42) | SMPD1 | |
| SCHEMBL3279603 | 0.74 | GRM4 (0.32) | SMPD1 | |
| SCHEMBL8896983 | 0.73 | CA1 (0.44) | CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-9795586-B2 | HNF4-α antagonist and use thereof | NATIONAL CANCER CENTER (KR) | 2017-10-24 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | NATIONAL CANCER CENTER (KR) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189371-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | CA1 2996/4885SMPD1 4868/4885 |
| US-20160193238-A1 | HNF4-alpha ANTAGONIST AND USE THEREOF | HNF4A, TCF4, WNT3A | CA1 2996/4885SMPD1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.